SENATORS AND SK-PHARMACEUTICALS VISITED THE KARAGANDA PHARMACEUTICAL COMPLEX

Continuing preparations for the round table on the topic “State and prospects for the development of the pharmaceutical industry,” deputies of the Senate of the Parliament of the Republic of Kazakhstan, together with representatives of the Single Distributor, visited the Karaganda pharmaceutical complex.

Karaganda Pharmaceutical Complex (KPC) is one of the leading domestic enterprises in the pharmaceutical industry in Kazakhstan. The complex is equipped with modern equipment and produces a wide range of medicines that comply with international quality standards.

First of all, the guests were shown a video about the activities of the enterprise, after which the complex employees conducted a safety briefing on the territory of the enterprise.

Then the delegation visited the workshop for lyophilized injectable drugs, where antibiotics, analgesics and other vital drugs are produced. Each stage of production undergoes strict quality control, ensuring the safety and effectiveness of the products.

The next location was the research laboratories of the quality control department: biochemical, physical-chemical and microbiological. Each laboratory plays a key role in the quality control system, ensuring product safety, effectiveness and compliance with international standards.

After a tour of the pharmaceutical complex, a final meeting was held with the participation of senators, representatives of the Single Distributor and the management of the enterprise. The parties discussed current issues related to providing the population with safe, effective and high-quality medicines, as well as the prospects for the development of the pharmaceutical industry in Kazakhstan.

Particular attention was paid to the development of domestic production. It is known that the Head of State has instructed to intensify cooperation with global pharmaceutical corporations, expand the volume and range of offtake contracts with domestic manufacturers and increase the share of domestically produced medicines and medical devices to 50% by 2025.

Thanks to effective government support measures, the Kazakhstan pharmaceutical industry has enormous potential to reduce import dependence. In the pharmaceutical industry this is represented in the form of long-term contracts. Over the past 15 years, there has been a systematic increase in the share of Kazakhstani drugs in the procurement of the Single Distributor, most of which are purchased through long-term contracts.

To date, 4 long-term contracts have been concluded between the Single Distributor and the Karaganda Pharmaceutical Complex for the supply of 39 types of medicines. Deliveries have been carried out since 2018.

It is worth noting the dynamic growth in the share of purchases from domestic manufacturers. If in 2018 the Karaganda pharmaceutical complex supplied 4 medicines worth 700 million tenge, then in 2024 this figure is about 8 billion tenge for the supply of 11 types of medicine.

As part of a long-term supply agreement, the Karaganda Pharmaceutical Complex has established the production and supply of generic and biotechnological medications for the treatment of severe socially significant diseases (oncology, hemophilia, hepatitis, diabetes and others), which were not previously produced in the country.

Summing up the meeting, the parties expressed gratitude for the constructive dialogue. They also expressed their readiness to jointly create favorable conditions for attracting investments and developing infrastructure, which will help increase the competitiveness of Kazakhstani products on the world market.